Xilio Therapeutics (NASDAQ:XLO – Get Rating) had its price objective dropped by equities researchers at Guggenheim to $15.00 in a research note issued on Tuesday, Stock Target Advisor reports.
Several other equities analysts have also recently weighed in on XLO. Raymond James dropped their price objective on Xilio Therapeutics from $31.00 to $13.00 and set an "outperform" rating for the company in a report on Thursday, November 10th. Morgan Stanley reduced their price objective on shares of Xilio Therapeutics from $32.00 to $20.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 10th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $16.00.
Get Xilio Therapeutics alerts:Xilio Therapeutics Stock Performance
Xilio Therapeutics stock traded down $0.06 during midday trading on Tuesday, hitting $2.40. The company's stock had a trading volume of 23,389 shares, compared to its average volume of 77,624. The company has a debt-to-equity ratio of 0.04, a current ratio of 8.45 and a quick ratio of 8.45. The company has a market cap of $65.93 million and a price-to-earnings ratio of -0.71. Xilio Therapeutics has a 1-year low of $2.01 and a 1-year high of $27.95. The company has a 50-day moving average price of $2.55 and a two-hundred day moving average price of $2.74.
Institutional Investors Weigh In On Xilio Therapeutics
A number of hedge funds have recently made changes to their positions in the stock. Laurion Capital Management LP acquired a new position in Xilio Therapeutics in the 2nd quarter worth about $417,000. State Street Corp increased its stake in shares of Xilio Therapeutics by 58.5% in the first quarter. State Street Corp now owns 93,861 shares of the company's stock valued at $664,000 after buying an additional 34,651 shares during the period. Renaissance Technologies LLC bought a new position in Xilio Therapeutics in the 2nd quarter valued at approximately $220,000. Millennium Management LLC bought a new position in Xilio Therapeutics in the 2nd quarter valued at approximately $146,000. Finally, Bailard Inc. bought a new position in Xilio Therapeutics in the 2nd quarter valued at approximately $107,000. 64.66% of the stock is currently owned by institutional investors and hedge funds.Xilio Therapeutics Company Profile
(Get Rating)
Xilio Therapeutics, Inc, a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors.
Featured Articles
- Get a free copy of the StockNews.com research report on Xilio Therapeutics (XLO)
- Don't Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe's?
- Agilent Remains In Buy Range Ahead Of Next Week's Q4 Report
- Three Penny Stocks Making Big Moves In November
- Wayfair Still Has Its Fair Share of Issues
Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.